Form 4: Director Gary Ng Acquires Niagen Bioscience Stock Options

Director Gary Ng acquired stock options for 31,746 shares of Niagen Bioscience (NAGE) on June 24, 2026, with a vesting date of June 24, 2027.

Summary

• Gary Ng, a Director at Niagen Bioscience, Inc. (NAGE), acquired stock options on June 24, 2026.
• The transaction grants Ng the right to purchase 31,746 shares of common stock.
• The exercise price for these options is $3.45 per share.
• These options are set to vest fully on June 24, 2027.
• The expiration date for these options is June 23, 2036.
• Following the transaction, Ng beneficially owns 31,746 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating alignment of interests, but does not provide new financial performance data.

Positives

• Director Gary Ng's acquisition of stock options indicates a potential alignment of management's interests with shareholders.
• The acquisition of a significant number of options (31,746) suggests confidence in the company's future prospects.

Risks

• The value of the acquired stock options is subject to market fluctuations and the company's future performance.
• If the stock price does not exceed the exercise price of $3.45 by the expiration date, the options may expire worthless.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is directly tied to the stock price.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to incentivize leadership and align their financial interests with long-term shareholder value creation. The specific exercise price and vesting schedule will be critical factors in assessing the true value of this grant.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive sign of management commitment, potentially aligning their interests with shareholders. However, the actual impact depends on future stock performance.
• Employees: While not directly impacted, employee morale can be influenced by perceived alignment and confidence of leadership.
• Management: Director Gary Ng benefits directly from this option grant, with potential for significant financial gain if the company's stock price increases.

Next Steps

• The stock options will vest on June 24, 2027.
• The options can be exercised anytime between the vesting date and the expiration date of June 23, 2036.

Key Dates

Keywords

stock options, insider trading, Niagen Bioscience, NAGE, director, beneficial ownership, SEC Form 4